{
  "pmcid": "4122593",
  "sha256": "23c4fb920552a10552d26eb7fb7e8509b6e4cb36c1c5bbf2da7507d1eed3bad4",
  "timestamp_utc": "2025-11-09T15:57:26.990420+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 15.609882386689616,
    "reading_ease": 14.825873493975934,
    "word_count": 249
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "S0220 was designed to incorporate an active systemic agent, (docetaxel) as consolidation therapy."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "The accrual goal was 45 eligible patients."
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with histologically-proven and radiologically-defined T3-T4, N0-N1, M0 SS NSCLC underwent induction therapy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Induction therapy with cisplatin-etoposide, concurrently with thoracic RT 45 Gy. Non-progressing patients underwent surgical resection within 7 weeks. Consolidation consisted of docetaxel every 3 weeks for 3 doses."
      },
      "Objective": {
        "score": 1,
        "evidence": "The primary objective was feasibility."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary objective was feasibility."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 46 patients registered, 44 were eligible and assessable; 38 (86%) completed induction."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 46 patients registered, 44 were eligible and assessable; 38 (86%) completed induction."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The 3-year progression-free survival is 56% and 3-year overall survival is 61%."
      },
      "Harms": {
        "score": 1,
        "evidence": "2 (7%) died of ARDS."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  }
}